Arndt Vogel, Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School, shared a post on X:
“Zanidatamab plus chemotherapy as first-line treatment for HER2-positive GC/GEJ cancer, published in the Lancet Oncology.
Single-arm, phase 2
– ORR 76·2%
– mPFS 12·5 mo
– mOS 36·5 mo
Looks promising, now combo with ICI, phase 3 awaited.”
Title: Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study
Journal: Lancet Oncology
Authors: Elena Elimova, Jaffer Ajani, Howard Burris, Crystal S. Denlinger, Syma Iqbal, Yoon-Koo Kang, Jwa Hoon Kim, Keun-Wook Lee, Bruce Lin, Rutika Mehta, Do-Youn Oh, Sun Young Rha, Young Mi Seol, Lin Yang, Mark A. Ozog, Phillip M. Garfin, Geoffrey Ku
More posts featuring Arndt Vogel on OncoDaily.